Vaccine Therapy in Preventing Cytomegalovirus Infection in Patients With Hematological Malignancies Undergoing Donor Stem Cell Transplant

Inclusion Criteria: * HLA A\*0201 subtype * CMV seropositive * Able and willing to sign the informed consent form (ICF) * Willingness to be followed for the planned duration of the trial (6 months post-HCT) * Seronegative for human immunodeficiency virus (HIV), hepatitis C virus (HCV) and active hepatitis B virus (HBV) (surface antigen negative) * Planned related or unrelated HCT, with 8/8 or 7/8 (A, B, C, DRB1) high resolution HLA donor allele matching * HCT for the treatment of hematologic cancers including, but not limited to: * Acute lymphoblastic leukemia in first or second remission (for acute lymphoblastic leukemia/lymphoblastic lymphoma, the disease status needs to be in hematologic remission by bone marrow/peripheral blood; persistent lymphadenopathy on computed tomography \[CT\] or CT/positron emission tomography \[PET\] scan without progression is allowed) * Chronic myelogenous leukemia in first chronic or accelerated phase, or in second chronic phase * Hodgkin and non-Hodgkin lymphoma * Myelodysplastic syndrome * Planned HCT with minimal to no-T cell depletion of graft * Use of contraception up to 90 days post-HCT * Negative pregnancy test for female recipient * DISEASE STATUS: Recipients to be enrolled are patients eligible for allogeneic HCT, who were diagnosed with hematologic cancers including: * Acute lymphoblastic leukemia (ALL); B-precursor ALL; T cell ALL * Acute myeloid leukemia (AML), acute promyelocytic leukemia; treatment related AML * Chroni…